Global Life Science Ventures — Investing in the life sciences

Global Life Science Ventures (GLSV) was a leading, independent venture capital fund focusing exclusively on the life sciences. GLSV was dedicated to supporting early-stage groups, originating from universities, scientific institutions or industry. The fund also invested in selected later stage companies, including buy-outs. For this purpose, GLSV provided finance, advice and access to expertise and networks. The group advised and managed funds totaling more than € 200 million. With offices in Germany and Switzerland, GLSV acted as one team with a global perspective.
The first fund started its activities in 1996 and invested in 18 companies. The second fund GLSV II started in 2001 and invested in 18 companies primarily in Europe and the US. After termination of the investment period, the fund exited the remaining assets in 2015 and is in liquidation.

Currenty, no new investments are being sought.

Text size

Investment Practice

identifying market potential
meeting unmet medical needs
delivering return on investment

GLSV predominantly focuses on making investments in early-stage companies. Through its close contacts with academic and institutional centres of excellence, GLSV is able to identify companies that have innovative technologies with considerable market potential. In certain cases, GLSV may also decide to invest in later stage companies, including buy-outs, which fulfil its investment criteria.

By building on the foundation of its investment philosophy, GLSV is able to deliver the best possible investment practice to its portfolio companies.